Pharmaceutical Preparations · NYSE
For the period ended December 31, 2025, AbbVie Inc. reported $61.2 billion across 12 geographies: United States ($46.60B, 76.2%), All other countries ($5.76B, 9.4%), Germany ($1.74B, 2.8%), Japan ($1.27B, 2.1%), and 8 smaller geographies. United States's share of the total is up from 71.9% for the period ended December 31, 2019.
AbbVie Inc. annual revenue by geography, as disclosed in SEC filings.
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| United States | $43.51B | $45.71B | $41.88B | $43.03B | $46.60B | 76.2% |
| All other countries | $4.76B | $4.84B | $5.04B | $5.45B | $5.76B | 9.4% |
| Germany | $1.22B | $1.34B | $1.27B | $1.47B | $1.74B | 2.8% |
| Japan | $1.09B | $956.0M | $1.01B | $1.12B | $1.27B | 2.1% |
| Canada | $1.40B | $1.16B | $1.08B | $1.09B | $1.22B | 2.0% |
| China | $857.0M | $912.0M | $950.0M | $917.0M | $1.01B | 1.6% |
| France | $936.0M | $787.0M | $780.0M | $776.0M | $806.0M | 1.3% |
| United Kingdom | $497.0M | $462.0M | $417.0M | $522.0M | $626.0M | 1.0% |
| Spain | $519.0M | $506.0M | $501.0M | $528.0M | $609.0M | 1.0% |
| Italy | $506.0M | $444.0M | $484.0M | $511.0M | $580.0M | 0.9% |
| Brazil | $368.0M | $430.0M | $439.0M | $464.0M | $478.0M | 0.8% |
| Australia | $533.0M | $508.0M | $472.0M | $463.0M | $459.0M | 0.8% |
| Total | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
Combined from XBRL segment tags and the segment tables in the company’s SEC filings. Figures are as reported and are not restated or adjusted.
Data: SEC EDGAR (financials, KPIs, segments) · Yahoo Finance (price, splits, metrics, analyst estimates, news headlines). Not financial advice.